Last reviewed · How we verify
Placebo matching Dapagliflozin
Placebo matching Dapagliflozin is a Small molecule drug developed by University Hospital Tuebingen. It is currently FDA-approved for Control comparator in clinical trials of dapagliflozin.
This is a placebo formulation matched to dapagliflozin, containing no active pharmaceutical ingredient, used as a control in clinical trials.
This is a placebo formulation matched to dapagliflozin, containing no active pharmaceutical ingredient, used as a control in clinical trials. Used for Control comparator in clinical trials of dapagliflozin.
At a glance
| Generic name | Placebo matching Dapagliflozin |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo matching dapagliflozin is an inert comparator designed to match the appearance, taste, and administration schedule of dapagliflozin (an SGLT2 inhibitor) in blinded clinical trials. It contains no active drug and serves as a control to assess the true efficacy of dapagliflozin by comparing outcomes between treatment and placebo groups while maintaining blinding.
Approved indications
- Control comparator in clinical trials of dapagliflozin
Common side effects
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (PHASE3)
- Dapagliflozin for Long COVID Syndrome (PHASE3)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (PHASE3)
- Dapagliflozin in Active Lupus Nephritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Dapagliflozin CI brief — competitive landscape report
- Placebo matching Dapagliflozin updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI
Frequently asked questions about Placebo matching Dapagliflozin
What is Placebo matching Dapagliflozin?
How does Placebo matching Dapagliflozin work?
What is Placebo matching Dapagliflozin used for?
Who makes Placebo matching Dapagliflozin?
What development phase is Placebo matching Dapagliflozin in?
Related
- Manufacturer: University Hospital Tuebingen — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Control comparator in clinical trials of dapagliflozin
- Compare: Placebo matching Dapagliflozin vs similar drugs
- Pricing: Placebo matching Dapagliflozin cost, discount & access